Dennis J. Slamon
0000-0002-6330-498X
Publication & Citation Trends
Publications
0 total
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
Cited by 11
Semantic Scholar
Abstract P3-11-10: Benefit/risk relationship of TCH versus AC-TH in BCIRG 006: analysis using generalized pairwise comparisons
Cited by 0
Semantic Scholar
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials
Cited by 0
Semantic Scholar
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ERBB2-Negative Early Breast Cancer
Cited by 14
Semantic Scholar
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients
Cited by 3
Semantic Scholar
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer
Cited by 2
Semantic Scholar
Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies OA
Cited by 2
Semantic Scholar
Abstract PO2-11-06: Anti-Müllerian hormone in Young women with breast CAncer to predict permanent loss of ovarian function after chemotherapy and anti-HER2 therapy (AMYCA): a biomarker analysis of the BETH and KAITLIN trials
Cited by 0
Semantic Scholar
Research Topics
HER2/EGFR in Cancer Research
(379)
Monoclonal and Polyclonal Antibodies Research
(233)
Advanced Breast Cancer Therapies
(219)
Cancer Treatment and Pharmacology
(93)
Lung Cancer Research Studies
(84)
Affiliations
University College Dublin
Université Paris-Sud
AstraZeneca (United Kingdom)
Hiroshima University
University of Southern California